Abstract
Therapeutic DNA cancer vaccines are now widely regarded as a potential technique for stimulating the immune system's response to cancer. Several clinical experiments involving plasmid DNA vaccines have already the induction of a wide and targeted immune response. Unfortunately, due to the tumor's immunosuppressive mechanisms, these vaccinations often showed very modest therapeutic results in clinical trials. This paper looks at how DNA vaccines for prostate cancer are progressing, as well as colorectal cancer clinical trials. This paper also examines the rationale for various treatment combinations and antigen selection strategies being developed to circumvent the limits of the cancer DNA vaccine. This paper focuses on the most promising discoveries as well as major concerns that must be addressed before therapeutic cancer DNA vaccines may be approved as part of standard cancer care for prostate cancer and colorectal cancer.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
